AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A mucoadhesive composition for solubilization of insoluble drugs

Docket No.: 4698-0110PUS1

comprising  $4\sim90$  % by weight of at least one monoglyceride compound and  $0.01\sim90$  % by

weight of at least one oil.

2. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to. Claim 1, additionally comprising 0.01 ~ 90 % by weight of at least one emulsifier.

3. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 1, wherein said monoglyceride compound is chosen from a saturated or an

unsaturated monoglyceride having 10 ~ 22 carbon atoms in the hydrocarbon chain.

4. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 3, wherein said monoglyceride compound is chosen from monoolein,

monopalmitolein, monomyristolein, monoelaidin, monoerucin, mixture of monoglycerides semi-

synthesized from triglycerides of vegetable or animal oil.

5. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 1, wherein said oil is chosen from triglyceride, iodized oil, vegetable oil and

3

animal oil.

Art Unit 1615

Reply to Office Action of October 28, 2008

6. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 5, wherein said triglyceride is chosen from saturated and unsaturated

triglyceride having  $2 \sim 20$  carbon atoms in each hydrocarbon chain.

7. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 6, wherein said triglyceride is chosen from triacetin, tributyrin, tricaproin,

tricaprylin, tricaprin and triolein; wherein said iodized oil is chosen from Lipiodol, iodized

poppy seed oil, Ethiodol and iodized soybean oil; wherein said vegetable oil is chosen from

soybean oil, cottonseed oil, olive oil, poppy seed oil, linseed oil, sesame oil; and wherein said

animal oil is chosen from squalane and squalene.

8-10. (Canceled)

11. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 2, wherein said emulsifier is chosen from a phospholipid, a non-ionic

surfactant, an anionic surfactant, a cationic surfactant and a bile acid.

12. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 11, wherein said phospholipid is chosen from a phosphatidylcholine (PC) and

its derivative, a phosphatidylethanolamine (PE) and its derivative, a phosphatidylserine (PS) and

its derivative, and a polymeric lipid wherein a hydrophilic polymer is to conjugated to the lipid

headgroup; wherein said non-ionic surfactant is chosen from a poloxamer (Pluronic:

4

CAM/KKC/vas

Art Unit 1615

Reply to Office Action of October 28, 2008

polyoxyethylene-polyoxypropylene copolymer), a sorbitan ester (sorbitan esters; Span), a

polyoxyethylene sorbitan (Tween) and a polyoxyethylene ether (Brij); wherein said anionic

surfactant is chosen from a phosphatidylserine (PS) and its derivative, a phosphatidic acid (PA)

and its derivative and sodium dodecyl sulfate (SDS); wherein said cationic surfactant is chosen

from 1,2-dioleyl-3-trimethylammonium propane (DOTAP), dimethyldioctadecylammonium

bromide (DDAB), N-[1-(1,2-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride

(DOTMA), 1,2-dioleyl-3-ethylphosphocholic acid (DOEPC) and 3β-[N-[(N',N'-

dimethylamino)ethan]carbamoyl]cholesterol (DC-Chol); and wherein said bile acid is chosen

from cholic acid, its salt and derivatives; deoxycholic acid, its salt and derivatives; chenocholic

acid, its salt and derivatives; and lithocholic acid, its salt and derivatives.

13-16. (Canceled)

17. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 1, additionally comprising  $0.01 \sim 5$  % by weight of another additive.

18. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 17, wherein the other additive is chosen from Cremophor, tocopherol,

tocopherol acetate, fatty acids, fatty acid esters, fatty acid alcohols, alcohols and polyols.

19. (Withdrawn) The mucoadhesive composition for solubilization of insoluble drugs

according to Claim 18, wherein the other additive is chosen from an alcohol chosen from

Art Unit 1615

Reply to Office Action of October 28, 2008

methanol, ethanol, propanol and isopropanol; and a polyol chosen from ethyleneglycol,

propyleneglycol and polyethyleneglycol.

20. (Canceled)

21. (Withdrawn) A preparation method of mucoadhesive composition for solubilization

of insoluble drugs according to Claim 1, wherein said method comprises the step of preparing a

viscous liquid by solubilizing at least 4 ~ 90 % by weight of at least one monoglyceride

compound in  $0.01 \sim 90$  % by weight of at least one oil.

22. (Withdrawn) The preparation method according to Claim 21, wherein the said

mixture is heated to 50°C to speed up the solubilization process.

23. (Withdrawn) A preparation method of mucoadhesive composition for solubilization

of insoluble drugs according to Claim 2, wherein said method comprises the step of preparing a

viscous liquid by mixing at least  $4 \sim 90$  % by weight of at least one monoglyceride compound

and  $0.01 \sim 90$  % by weight of at least one oil with  $0.01 \sim 90$  % by weight of at least one

emulsifier.

24. (Withdrawn) The preparation method according to Claim 23 wherein the said mixture

is heated to 50 °C to speed up the solubilization process.

6

CAM/KKC/vas

Art Unit 1615

Reply to Office Action of October 28, 2008

25. (Withdrawn) The preparation method according to Claim 23 wherein the said mixture

is sonicated in a bath type sonicator to speed up the solubilization process.

26. (Currently Amended) A mucoadhesive formulation for solubilization of insoluble

drugs comprising 4 - 90 % by weight 4 to 90 % by weight of at least one monoglyceride

compound monoolein, 0.01 - 90 % by weight 0.01 to 90 % by weight of at least one oil selected

from the group consisting of triacetin, tributyrin, tricaproin, tricaprylin, tricaprin, triolein,

Lipiodol, iodized poppy seed oil, Ethiodol, iodized soybean oil, soybean oil, cottonseed oil, olive

oil, poppy seed oil, linseed oil, sesame oil, squalane and squalene and 0.01 - 20 % by weight

0.01 to 20 % by weight of at least one insoluble drug.

27. (Currently Amended) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 26, additionally containing 0.01 - 90 % by weight 0.01 to 90 % by

weight of at least one emulsifier.

28-34. (Canceled)

35. (Currently Amended) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 27, wherein said emulsifier is selected from the group consisting of a

phospholipid, a non-ionic surfactant, an anionic surfactant, a cationic surfactant and a bile acid.

7

CAM/KKC/vas

Art Unit 1615

Reply to Office Action of October 28, 2008

36. (Currently Amended) The mucoadhesive formulation for solubilization of insoluble drugs according to Claim 35,

Docket No.: 4698-0110PUS1

wherein said phospholipid is chosen from a phosphatidylcholine (PC) and its derivative, a phosphatidylethanolemine (PE) and its derivative, a phosphatidylserine (PS) and its derivative and a polymeric lipid wherein a hydrophilic polymer is conjugated to-the a lipid headgroup;

wherein said non-ionic surfactant is chosen from a poloxamer (Pluronic: polyoxyethylene-polyoxypropylene copolymer), a sorbitan ester (sorbitan esters; Span), a polyoxyethylene sorbitan (Tween) and a polyoxyethylene ether (Brij);

wherein said anionic surfactant is chosen from a phosphatidylserine (PS) and its derivative, a phosphatidic acid (PA) and its derivative-or and sodium dodecyl sulfate (SDS);

wherein said cationic surfactant is chosen from 1,2-dioleyl-3-trimethylammonium dimethyldioctadecylammonium (DOTAP), propane bromide (DDAB), N-[1-(1,2dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1,2-dioleyl-3ethylphosphocholic acid (DOEPC) and  $3\beta-[N-[(N',N'$ dimethylamino)ethan]carbamoyl]cholesterol (DC-Chol); and

wherein said bile acid is chosen from cholic acid, its salt and derivatives; deoxycholic acid, its salt and derivatives; chenocholic acid, its salt and derivatives; and lithocholic acid, its salt and derivatives.

8

37 - 40. (Canceled)

Art Unit 1615

Reply to Office Action of October 28, 2008

41. (Currently Amended) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 26, wherein said bioactive compound the at least one insoluble drug is

chosen from antivirals, steroidal anti-inflammatory drugs (SAID), non-steroidal anti-

inflammatory drugs (NSAID), antibiotics, antifungals, vitamins, hormones, prostaglandins,

prostacyclins, anticancer drugs, antimetabolitic drugs, miotics, cholinergies, adrenergic

antagonists, anticonvulsants, antianxiety agents, major tranquilizers, antidepressants, anesthetics,

analgesics, anabolic steroids, estrogens, progesterones, glycosaminoglycans, polynucleotides,

immunosuppressants and immunostimulants.

42. (Currently Amended) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 26, additionally comprising 0.01 ~ 5 % by weight 0.01 to 5 % by

weight of another additives. additive.

43. (Previously Presented) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 42, wherein the other additive is chosen from Cremophor, tocopherol,

tocopherol acetate, fatty acids, fatty acid esters, fatty acid alcohols, alcohols and polyols.

44. (Previously Presented) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 43, wherein the additive is chosen from an alcohol chosen from

methanol, ethanol, propanol and isopropanol; and a polyol chosen from ethyleneglycol and

polyethyleneglycol.

9

CAM/KKC/vas

Art Unit 1615

Reply to Office Action of October 28, 2008

45. (Canceled)

46. (Currently Amended) The mucoadhesive formulation for solubilization of insoluble

Docket No.: 4698-0110PUS1

drugs according to Claim 26, wherein the formulation is suitable for administration route is

ehosen from oral administration, buccal administration, mucosal administration, intranasal

administration, intraperitoneal administration, subcutaneous injection, intramuscular injection,

transdermal administration [[and]] or intratumoral injection.

47. (Previously Presented) The mucoadhesive formulation for solubilization of insoluble

drugs according to Claim 26 existing in liquid or semi-solid form.

48. (Withdrawn) A method of preparing the mucoadhesive formulation for solubilization

of insoluble drugs according to Claim 26, wherein said method comprises the steps of:

1) solubilizing  $4 \sim 90$  % by weight of at least one monoglyceride compound in  $0.01 \sim 90$ 

% by weight of at least one oil (step 1); and

2) solubilizing completely  $0.01 \sim 20$  % by weight of at least one insoluble drug in said

mixture in step (1) by stirring (step 2).

49. (Withdrawn) The preparation method according to Claim 48 wherein the said mixture

is heated to 50 °C in step (1) to speed up the solubilization process.

Art Unit 1615

Reply to Office Action of October 28, 2008

Docket No.: 4698-0110PUS1

50. (Withdrawn) The preparation method according to Claim 48 wherein the said mixture

is sonicated in a bath type sonicator in step (2) to speed up the solubilization process.

51. (Withdrawn) A preparation method of mucoadhesive formulation for solubilization of

insoluble drugs according to Claim 26, wherein said method comprises the step of preparing a

homogenous liquid by mixing completely at least one monoglyceride compound, at least one oil

and insoluble drug.

52. (Withdrawn) The preparation method according to Claim 51 wherein the said mixture

is heated to 50°C and sonicated in a bath type sonicator to speed up the solubilization process.

53. (Withdrawn) A method of preparing the mucoadhesive formulation for solubilization

of insoluble drugs according to Claim 27, wherein said method comprises the steps of:

1) preparing a viscous liquid by mixing completely  $4 \sim 90$  % by weight of at least one

monoglyceride compound,  $0.01 \sim 90$  % by weight of at least one oil and  $0.01 \sim 90$  % of at least

one emulsifier (step 1); and

2) preparing a viscous liquid by mixing completely insoluble drug with said liquid in step

(1) (step 2).

54. (Withdrawn) The preparation method according to Claim 53 wherein the said liquid is

heated to 50 °C in step (1) to speed up the solubilization process.

11

Docket No.: 4698-0110PUS1

55. (Withdrawn) The preparation method according to Claim 53 wherein the said liquid is heated to 50 °C in step (2) to speed up the solubilization process.

56. (Withdrawn) The preparation method according to Claim 53 wherein the said liquid is

sonicated in a bath type sonicator in step (2) to speed up the solubilization process.

57. (Withdrawn) A method of preparing the mucoadhesive formulation for solubilization

of insoluble drugs according to Claim 27, wherein said method comprises the steps of:

1) preparing oily liquid containing drug by solubilizing completely  $0.01 \sim 20$  % by

weight of insoluble drug in  $0.01 \sim 90$  % by weight of at least one oil (step 1); and

2) preparing a homogeneous liquid by mixing completely said liquid in step (1) with  $4 \sim$ 

90 % by weight of at least one monoglyceride compound and  $0.01 \sim 90$  % of at least one

emulsifier (step 2).

58. (Withdrawn) The preparation method according to Claim 57, wherein the said liquid

is heated to 50 °C and sonicated in a bath type sonicator in step (2) to speed up the solubilization

process.

12